Nautilus Biotechnology, Inc.
General ticker "NAUT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $140.6M (TTM average)
Nautilus Biotechnology, Inc. follows the US Stock Market performance with the rate: 43.4%.
Estimated limits based on current volatility of 7.8%: low 2.24$, high 2.61$
Factors to consider:
- Total employees count: 155 (-7.2%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Dependence on proteomics platform, High R&D costs, Market competition, Third-party risks, Geopolitical risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.38$, 3.42$]
- 2026-12-31 to 2027-12-31 estimated range: [1.29$, 3.10$]
Financial Metrics affecting the NAUT estimates:
- Positive: with PPE of -4.1 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -20.64 <= 0.01
- Positive: -4.75 < Operating profit margin, % of 0
- Positive: Investing cash flow per share per price, % of 14.34 > -0.63
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 82.14 > 64.29
- Negative: negative Net income
Short-term NAUT quotes
Long-term NAUT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $76.15MM | $81.48MM | $0.00MM |
| Operating Income | $-76.15MM | $-81.48MM | $0.00MM |
| Non-Operating Income | $12.48MM | $10.70MM | $-59.00MM |
| R&D Expense | $47.25MM | $50.48MM | $41.11MM |
| Income(Loss) | $-63.67MM | $-70.78MM | $-59.00MM |
| Profit(Loss)* | $-63.67MM | $-70.78MM | $-59.00MM |
| Stockholders Equity | $265.35MM | $208.73MM | $156.97MM |
| Assets | $305.56MM | $242.74MM | $191.11MM |
| Operating Cash Flow | $-51.71MM | $-59.15MM | $-50.70MM |
| Capital expenditure | $2.44MM | $2.12MM | $1.28MM |
| Investing Cash Flow | $-43.73MM | $66.25MM | $35.22MM |
| Financing Cash Flow | $0.37MM | $1.14MM | $0.21MM |
| Earnings Per Share** | $-0.51 | $-0.56 | $-0.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.